The Renin Angiotensin Aldosterone System in Obesity and Hypertension: Roles in the Cardiorenal Metabolic Syndrome

Medical Clinics of North America

Volumn 101, Issue 1, 2017, Pages 129-137

  Cabandugama, Peminda K ^a   Gardner, Michael J ^a   Sowers, James R ^a,b,c  

^a University of Missouri   (United States)

^b UNIVERSITY OF MISSOURI   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Adipocyte; Angiotensin II; Hypertension; Insulin resistance; Obesity

Indexed keywords

ALISKIREN; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; LISINOPRIL; MINERALOCORTICOID RECEPTOR; NITRIC OXIDE SYNTHASE; RENIN INHIBITOR; VALSARTAN; MINERALOCORTICOID ANTAGONIST; RENIN;

ACUTE HEART FAILURE; ADRENERGIC SYSTEM; CARDIORENAL SYNDROME; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; HUMAN; HYPERTENSION; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SODIUM METABOLISM; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; COMPLICATION; METABOLISM;

CARDIO-RENAL SYNDROME; HUMANS; HYPERTENSION; MINERALOCORTICOID RECEPTOR ANTAGONISTS; OBESITY; RENIN; RENIN-ANGIOTENSIN SYSTEM; SYMPATHETIC NERVOUS SYSTEM;

EID: 84996743333     PISSN: 00257125     EISSN: 15579859     Source Type: Journal    
DOI: 10.1016/j.mcna.2016.08.009     Document Type: Review

References (44)

1. 1 Ronco, C., The cardiorenal syndrome: basis and common ground for a multidisciplinary patient-oriented therapy. Cardiorenal Med 1 (2011), 3–4.
2. 2 Available at: http://www.cdc.gov/nchs/data/nhis/earlyrelease/earlyrelease201602_06.pdf. Accessed June 20, 2016.
3. 3 Hoerger, T.J., Simpson, S.A., Yarnoff, B.O., et al. The future burden of CKD in the United States: a simulation model for the CDC CKD Initiative. Am J Kidney Dis 65:3 (2015), 403–411.
4. 4 Landsberg, L., Aronne, L.J., Beilin, L.J., et al. Obesity related hypertension: pathogenesis, cardiovascular risk, and treatment-a position paper of the obesity society and the American society of hypertension. Obesity (Silver Spring) 21:1 (2013), 8–24.
5. 5 Aroor, A.R., Demarco, V.G., Jia, G., et al. The role of tissue renin-angiotensin-aldosterone system in the development of endothelial dysfunction and arterial stiffness. Front Endocrinol (Lausanne), 4, 2013, 161.
6. 6 Demarco, V.G., Aroor, A.R., Sowers, J.R., The pathophysiology of hypertension in patients with obesity. Nat Rev Endocrinol 10 (2014), 364–376.
7. 7 Manrique, C., Sowers, J.R., Insulin resistance and skeletal muscle vasculature: Significance, assessment and therapeutic modulators. Cardiorenal Med 4 (2014), 244–256.
8. 8 Messerli, F.H., Christie, B., DeCarvalho, J.G., et al. Obesity and essential hypertension. hemodynamics, intravascular volume, sodium excretion, and plasma renin activity. Arch Intern Med 141:1 (1981), 81–85.
9. 9 Frohlich, E.D., Messerli, F.H., Reisin, E., et al. The problem of obesity and hypertension. Hypertension 5:5 Pt 2 (1983), III71–III78.
10. 10 De Faria, A.P., Modolo, R., Fontana, V., et al. Adipokines: novel players in resistant hypertension. J Clin Hypertens 16:10 (2014), 754–759.
11. 11 Rahmouni, K., Obesity associated hypertension: recent progress in deciphering the pathogenesis. Hypertension 64 (2014), 215–221.
12. 12 Padilla, J., Vierira-Potter, V.J., Jia, G., et al. Role of perivascular adipose tissue on vascular reactive oxygen species in type 2 diabetes: a give and take relationship. Diabetes 64 (2015), 1904–1906.
13. 13 Engeli, S., Schling, P., Gorzelniak, K., et al. The adipose tissue renin-angiotensin-aldosterone system: role in the metabolic syndrome?. Int J Biochem Cell Biol 35 (2003), 807–825.
14. 14 Massiera, F., Seydoux, J., Geloen, A., et al. Angiotensinogen-deficient mice exhibit impairment of diet-induced weight gain with alteration in adipose tissue development and increased locomotor activity. Endocrinology 142 (2001), 5220–5225.
15. 15 Yvan-Charvet, L., Even, P., Bloch-Faure, M., et al. Deletion of the angiotensin type 2 receptor reduces adipose cell size and protects from diet-induced obesity and insulin resistance. Diabetes 54 (2005), 991–999.
16. 16 Yiannikouris, F., Gupte, M., Putnam, K., et al. Adipocyte deficiency of angiotensinogen prevents obesity-induced hypertension in male mice. Hypertension 60 (2012), 1524–1530.
17. 17 Mehta, P.K., Griendling, K.K., Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol 292 (2007), C82–C97.
18. 18 Briones, A.M., Nguyen Dinh Cat, A., Callera, G.E., et al. Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction. Hypertension 59 (2012), 1069–1078.
19. 19 Bender, S.B., Mcgraw, A.P., Jaffe, I.Z., et al. Mineralocorticoid receptor-mediated vascular insulin resistance: an early contributor to diabetes-related vascular disease?. Diabetes 62:2 (2013), 313–319.
20. 20 Jia, G., Habibi, J., Aroor, A.R., et al. Endothelial mineralocorticoid receptor mediates diet-induced aortic stiffness in females. Circ Res 118 (2016), 935–943.
21. 21 Troisi, R.J., Weiss, S.T., Parker, D.R., et al. Relation of obesity and diet to sympathetic nervous system activity. Hypertension 17 (1991), 669–677.
22. 22 Huggett, R.J., Burns, J., Mackintosh, A.F., et al. Sympathetic neural activation in nondiabetic metabolic syndrome and its further augmentation by hypertension. Hypertension 44 (2004), 847–852.
23. 23 Raumouni, K., Correla, M.I., Haynes, W.G., et al. Obesity associated hypertension: new insights into mechanisms. Hypertension 25 (2005), 9–14.
24. 24 Haynes, W.G., Morgan, D.A., Walsh, S.A., et al. Receptor-mediated regional sympathetic nerve activation by leptin. J Clin Invest 100 (1997), 270–278.
25. 25 Ozata, M., Ozdemir, I.C., Licinio, J., Human leptin deficiency caused by a missense mutation: multiple endocrine defects, decreased sympathetic tone, and immune system dysfunction indicate new targets for leptin action, greater central than peripheral resistance to the effects of leptin, and spontaneous correction of leptin-mediated defects. J Clin Endocrinol Metab 84 (1999), 3686–3695.
26. 26 Bravo, P.E., Morse, S., Borne, D.M., et al. Leptin and hypertension in obesity. Vasc Health Risk Manag 2:2 (2006), 163–169.
27. 27 Morgan, D.A., Thedens, D.R., Weiss, R., et al. Mechanisms mediating renal sympathetic activation to leptin in obesity. Am J Physiol Regul Integr Comp Physiol 295 (2008), R1730–R1736.
28. 28 Cooper, S.A., Whaley-Connell, A., Habibi, J., et al. Renin-angiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance. Am J Physiol Heart Circ Physiol 293 (2007), H2009–H2023.
29. 29 Kazumi, T., Kawaguchi, A., Katoh, J., et al. Fasting insulin and leptin levels are associated with systolic blood pressure independent of percentage body fat and body fat mass index. J Hypertens 17 (1999), 1451–1455.
30. 30 Grassi, G., Renin-angiotensin-sympathetic crosstalks in hypertension: reappraising the relevance of peripheral interactions. J Hypertens 19 (2001), 1713–1716.
31. 31 Raasch, W., Betge, S., Dendorfer, A., et al. Angiotensin converting enzyme inhibition improves cardiac neuronal uptake of noradrenaline in spontaneously hypertensive rats. J Hypertens 19 (2001), 1827–1833.
32. 32 Grassi, G., Seravalle, G., Cattaneo, B.M., et al. Sympathetic activation in obese normotensive subjects. Hypertension 25 (1995), 560–563.
33. 33 Gillespie, E.L., White, C.M., Kardas, M., et al. The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes. Diabetes Care 28 (2005), 2261–2266.
34. 34 Scheen, A.J., Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomized clinical trials. Diabetes Metab 30 (2004), 487–496.
35. 35 Reisin, E., Weir, M.R., Falkner, B., et al. For the Treatment in Obese Patients with Hypertension (TROPHY) study group. Hypertension 30:1 (1997), 140–145.
36. 36 Kintscher, U., Bramlage, P., Paar, W.D., et al. Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the treat to target post authorization survey. Prospective, observational two armed study in 14, 200 patients. Cardiovasc Diabetol, 6, 2007, 12.
37. 37 Zappe, D.H., Sowers, J.R., Hsueh, W.A., et al. Metabolic and antihypertensive effects of combined angiotensin receptor blocker and diuretic therapy in prediabetic hypertensive patients with the cardiometabolic syndrome. J Clin Hypertens 10:12 (2008), 894–903.
38. 38 Parving, H.H., Brenner, B.M., McMurray, J.J., et al. Cardiorenal end points in a trial of Aliskiren for type 2 diabetes. N Engl J Med 367:23 (2012), 2204–2213.
39. 39 Friedrich, S., Schmieder, R.E., Review of direct renin inhibition by Aliskiren. J Renin Angiotensin Aldosterone Syst 14:3 (2013), 193–196.
40. 40 Mancia, G., Fagard, R., Narkiewicz, K., et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC). J Hypertens 31 (2013), 1281–1357.
41. 41 James, P.A., Oparil, S., Carter, B.L., et al. 2014 Evidence based guideline for the management of high blood pressure in adults: report from the panel members appointment to the eighth Joint National Committee (JNC 8). JAMA 311:5 (2014), 507–520.
42. 42 Chobanian, A.V., Bakris, G.L., Black, H.R., et al. National heart, lung and blood institute joint national committee on prevention, detection, evaluation and treatment of high blood pressure; national high blood pressure education program coordinating committee. The seventh report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure: the JNC 7 report. JAMA 289:19 (2003), 2560–2572.
43. 43 National Clinical Guideline Centre, Hypertension: the clinical management of primary hypertension in adults: update of clinical guidelines 18 to 34. 2011, Royal College of Physicians, London.
44. 44 Dasqupta, K., Quinn, R.R., Zarnke, K.B., et al. The 2014 Canadian hypertension education program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention and treatment of hypertension. Can J Cardiol 30:5 (2014), 485–501.